RxDoctor Payments Data

Valerie le, MD

Allergy · Madison, ALNPI 1013371582

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.3% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AstraZeneca at 31.3% of the total.

$1,262in general payments, 2019–2025

Across 53 payments — averaging $23.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$394
  • Sanofi$197
  • Regeneron Healthcare Solutions, Inc.$164
  • Takeda Pharmaceuticals U.S.A., Inc.$123
  • Inspire Medical Systems, Inc.$119
  • GSK$82
  • plus $183 from 6 others

What the payments were for

  • Food & beverage$1,22897%
  • Education$343%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few allergy providers in Alabamato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$40,077
Medicare patients
89
Services billed
4,010

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$19,566
Ipratropium Bromide114$5,734
Breo ElliptaFluticasone/Vilanterol14$5,585
Epinephrine12$2,846
Fluticasone Propionate44$1,012
Famotidine50$796
Azelastine Hcl19$547
Albuterol Sulfate HfaAlbuterol Sulfate13$343
Montelukast Sodium26$292
Doxepin Hcl17$250
Levocetirizine Dihydrochloride26$198
Hydroxyzine Hcl28$134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$82$25,15133 claims
Hikma Pharmaceuticals USAEpinephrine$28$2,84612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Alabamaon file to place this against a meaningful peer group, so we don't.

Other allergy in Madison

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →